RxDoctor Payments Data

Kelsey Rader

Family · Lafayette, INNPI 1104479013

Payments from drug & device makers

$1,536in general payments, 2019–2025

Across 88 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$430
  • Supernus Pharmaceuticals, Inc.$265
  • Corium, LLC$190
  • AstraZeneca$73
  • Novo Nordisk$65
  • Exact Sciences$63
  • plus $451 from 15 others

What the payments were for

  • Food & beverage$1,536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,536 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$634
Medicare patients
28
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide18$16,202
MounjaroTirzepatide12$13,155
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,651
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,824
Pregabalin16$784
Levothyroxine Sodium61$777
Albuterol Sulfate HfaAlbuterol Sulfate39$775
Ventolin HfaAlbuterol Sulfate11$594
Atorvastatin Calcium82$515
Lisinopril80$429
Omeprazole39$371
Venlafaxine Hcl ErVenlafaxine Hcl11$327
Gabapentin36$313
Amlodipine Besylate49$304
Trazodone Hcl22$251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$60$29,35730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →